Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to evaluate the safety and effectiveness of Clareon™ PanOptix™ Pro Trifocal Intraocular Lens (IOL) compared to Clareon™ PanOptix™ Trifocal IOL.
Subjects will attend 9 scheduled study visits for a total individual duration of participation of approximately 6 months. The primary endpoint will be assessed at the Month 2 follow-up visit. Both eyes of a subject must qualify for enrollment into this study.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| CPO Pro IOL | Experimental | CPO Pro IOL implanted in the first eye, as randomized. The fellow eye will receive CPO IOL. The second eye surgery will occur approximately 7-14 days after the first eye surgery. |
|
| CPO IOL | Experimental | CPO IOL implanted in the first eye, as randomized. The fellow eye will receive CPO Pro IOL. The second eye surgery will occur approximately 7-14 days after the first eye surgery. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| CPO Pro IOL | Device | Intraocular lens (IOL) implanted in the eye for the visual correction of aphakia in adult patients with less than 1 diopter of preexisting corneal astigmatism in whom a cataractous lens has been removed. The IOL is intended to mitigate the effects of presbyopia on intermediate and near visual acuity while maintaining comparable distance visual acuity. The Clareon™ PanOptix™ Pro Trifocal IOL is designed to enhance distance image quality by reducing chromatic aberration. |
| Measure | Description | Time Frame |
|---|---|---|
| Mean Monocular Photopic Best Corrected Distance Visual Acuity (BCDVA) | Visual Acuity (VA) was assessed for each eye individually using Early Treatment Diabetic Retinopathy Study (ETDRS) reading charts at a distance of 4 meters from the subject under photopic (well-lit) conditions with correction in place. BCDVA was measured in logarithm Minimum Angle of Resolution (logMAR). LogMAR values typically range from -0.3 (20/10 vision on the Snellen chart) to 1 (20/200 vision), with lower scores indicating better vision. | Month 2 postoperative |
Not provided
Not provided
Key Inclusion Criteria:
Key Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Principal Clinical Trial Lead | Alcon Research, LLC | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Wolstan & Goldberg Eye Associates | Torrance | California | 90505 | United States | ||
| Grosinger, Spigelman & Grey Eye Surgeons, P.C. |
Not provided
| Label | URL |
|---|---|
| Plain Language Summaries of Study Results | View source |
| Educational | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Of the 71 randomized participants, 2 were discontinued after randomization and prior to attempted implantation. This reporting group includes all participants with attempted implantation (69). Note: One participant was implanted in one eye only (i.e., with CPO Pro IOL).
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | CPO Pro IOL / CPO IOL | CPO Pro IOL Model PAYWT0 implanted in one eye with CPO IOL Model CNWTT0 implanted in the other eye, as randomized. The second eye surgery occurred approximately 7-14 days after the first eye surgery. The CPO Pro IOL is designed to enhance distance image quality by reducing chromatic aberration. |
| Title | Milestones | Reasons Not Completed | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
All Implanted Analysis Set: All subjects with successful contralateral implantation, with at least one postoperative visit (same postoperative visit for both eyes).
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | CPO Pro IOL / CPO IOL | CPO Pro IOL Model PAYWT0 implanted in one eye with CPO IOL Model CNWTT0 implanted in the other eye, as randomized. The second eye surgery occurred approximately 7-14 days after the first eye surgery. |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Mean Monocular Photopic Best Corrected Distance Visual Acuity (BCDVA) | Visual Acuity (VA) was assessed for each eye individually using Early Treatment Diabetic Retinopathy Study (ETDRS) reading charts at a distance of 4 meters from the subject under photopic (well-lit) conditions with correction in place. BCDVA was measured in logarithm Minimum Angle of Resolution (logMAR). LogMAR values typically range from -0.3 (20/10 vision on the Snellen chart) to 1 (20/200 vision), with lower scores indicating better vision. | All Implanted Analysis Set: All subjects with successful contralateral implantation, with at least one postoperative visit (same postoperative visit for both eyes). | Posted | Mean | Standard Deviation | logMAR | Month 2 postoperative | eyes | eyes |
|
Adverse Events (AEs) were collected from time of consent to study exit, approximately 6 months. AEs were obtained through solicited and spontaneous comments from subjects and through observations by the investigator. "At Risk" population for ocular AEs is reported in units of eyes; all other populations are reported in units of subjects. This analysis population includes all eyes with attempted implantation (successful or aborted after contact with the eye).
All subjects were monitored for serious and other ocular and nonocular AEs. However, the nonocular AE arms were not considered at Risk for ocular adverse event terms as the arms are reporting nonocular-specific AEs. Similarly, the ocular AE arms were not considered at Risk for nonocular adverse event terms as the arms are reporting ocular-specific AEs. All-Cause Mortality was not monitored for the ocular arms.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Pretreatment | Adverse events occurring prior to attempted implantation with the IOL, including ocular adverse events in the second surgical eye that may have occurred prior to second eye attempted implantation. |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Cystoid macular oedema | Eye disorders | MedDRA 27.0 | Systematic Assessment |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Posterior capsule opacification | Eye disorders | MedDRA 27.0 | Systematic Assessment |
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Director Clinical Trial Management, Surgical IOL | Alcon Research, LLC | 1-888-451-3937 | alcon.medinfo@alcon.com |
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot | Yes | No | No | Study Protocol | Mar 18, 2025 | Nov 24, 2025 | Prot_000.pdf |
| SAP | No | Yes | No | Statistical Analysis Plan | Oct 4, 2024 | Nov 24, 2025 | SAP_001.pdf |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D001035 | Aphakia |
| D011305 | Presbyopia |
| D002386 | Cataract |
| ID | Term |
|---|---|
| D007905 | Lens Diseases |
| D005128 | Eye Diseases |
| D012030 | Refractive Errors |
Not provided
Not provided
| ID | Term |
|---|---|
| D002387 | Cataract Extraction |
| ID | Term |
|---|---|
| D054140 | Refractive Surgical Procedures |
| D013508 | Ophthalmologic Surgical Procedures |
| D013514 | Surgical Procedures, Operative |
Not provided
Not provided
Contralateral (split face) study design
Not provided
Not provided
Not provided
|
|
| CPO IOL | Device | Intraocular lens (IOL) implanted in the eye for the visual correction of aphakia in adult patients with less than 1 diopter of preexisting corneal astigmatism in whom a cataractous lens has been removed. The IOL is intended to mitigate the effects of presbyopia on intermediate and near visual acuity while maintaining distance visual acuity. |
|
|
| Cataract Surgery | Procedure | Extraction of the cataractous lens by phacoemulsification, followed by implantation of the IOL |
|
| Bloomfield Hills |
| Michigan |
| 48302 |
| United States |
| Moyes Eye Center | Kansas City | Missouri | 64154 | United States |
| Cincinnati Eye Institute | Cincinnati | Ohio | 45242 | United States |
| Carolina Eye Care Physicians | Charleston | South Carolina | 29414 | United States |
| Vision for Life | Nashville | Tennessee | 37205 | United States |
| Houston Eye Associates | Houston | Texas | 77008 | United States |
| The Eye Institute of Utah | Salt Lake City | Utah | 84107 | United States |
| years |
|
| Sex: Female, Male | Count of Participants | Participants | No |
|
| Ethnicity (NIH/OMB) | Count of Participants | Participants | No |
|
| Race/Ethnicity, Customized | Count of Participants | Participants | No |
|
| Region of Enrollment | Number | participants |
|
| OG001 | CPO IOL | CPO IOL Model CNWTT0 implanted in one eye during cataract surgery |
|
|
|
| 0 |
| 69 |
| 0 |
| 69 |
| 0 |
| 69 |
| EG001 | CPO Pro IOL (Ocular Adverse Events) | Ocular adverse events occurring after attempted implantation with CPO Pro IOL | 0 | 0 | 0 | 69 | 6 | 69 |
| EG002 | CPO IOL (Ocular Adverse Events) | Ocular adverse events occurring after attempted implantation with CPO IOL | 0 | 0 | 1 | 68 | 6 | 68 |
| EG003 | Systemic (Nonocular Adverse Events) | Nonocular adverse events occurring after attempted implantation with the IOL | 0 | 69 | 2 | 69 | 0 | 69 |
| Pneumonia | Infections and infestations | MedDRA 27.0 | Systematic Assessment |
|
| Thoracic vertebral fracture | Injury, poisoning and procedural complications | MedDRA 27.0 | Systematic Assessment |
|
Sponsor reserves the right of prior review of any publication or presentation of information related to the study.